Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimer's-like neuropathology and age-related alterations in mice

Molecular Neurobiology

Volumn 46, Issue 1, 2012, Pages 217-220

  Kupershmidt, Lana ^a   Amit, Tamar ^a   Bar Am, Orit ^a   Weinreb, Orly ^a   Youdim, Moussa B H ^a  

^a Eve Topf and USA National Parkinson Foundation   (Israel)

Author keywords

Ageing; Alzheimer's disease; Hypoxia inducible factor; Iron chelator; Multi functional drug; Neuroprotection; amyloid plaques

Indexed keywords

5 (N METHYL N PROPARGYLAMINOMETHYL) 8 HYDROXYQUINOLINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; HYPOXIA INDUCIBLE FACTOR; IRON CHELATING AGENT; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DRUG EFFECT; DRUG MECHANISM; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE;

EID: 84868093104     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-012-8304-7     Document Type: Article

References (21)

1. Weinreb O, Amit T, Mandel S, Kupershmidt L, Youdim MB (2010) Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal 13(6):919-949
2. Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT (2010) Novel drug targets based on metallobiology of Alzheimer's disease. Expert Opin Ther Targets 14(11):1177-1197
3. Olivares D, Huang X, Branden L, Greig NH, Rogers JT (2009) Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress: the role of a putative iron-responsive element. Int J Mol Sci 10(3):1226-1260
4. Roberts BR, Ryan TM, Bush AI, Masters CL, Duce JA (2012) The role of metallobiology and amyloid-β peptides in Alzheimer's disease. J Neurochem 120(Suppl 1):149-166
5. Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW Jr, Cohen ML, Wang X, Siedlak SL, Dwyer BE, Hayashi T, Nakamura M, Nunomura A, Perry G (2010) Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 19(1):363-372
6. Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MB, Fridkin M (2005) Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem 13(3):773-783 (Pubitemid 40093620)
7. Zheng H, Fridkin M, Youdim MB (2012) From antioxidant chelators to site-activated multi-target chelators targeting hypoxia inducing factor, beta-amyloid, acetylcholinesterase and monoamine oxidase A/B. Mini Rev Med Chem 12(5):364-370
8. Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46 (2):254-263 (Pubitemid 37532833)
9. Gal S, Zheng H, Fridkin M, Youdim MBH (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTPinduced striatal dopamine depletion. J Neurochem 95(1):79-88 (Pubitemid 41384427)
10. Gal S, Abassi ZA, Youdim MB (2010) Limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30. Neurotox Res 18(2):143-150
11. Gal S, Zheng H, Fridkin M, Youdim MB (2010) Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res 17(1):15-27
12. ZhuW, XieW, Pan T,Xu P, FridkinM, ZhengH, Jankovic J,Youdim MB, Le W (2007) Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brainpermeable iron chelators. FASEBJ 21(14):3835-3844 (Pubitemid 350232341)
13. Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB (2009) Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 23(11):3766-3779
14. Smith TG, Talbot NP (2010) Prolyl hydroxylases and therapeutics. Antioxid Redox Signal 12(4):431-439
15. Gorres KL, Raines RT (2010) Prolyl 4-hydroxylase. Crit Rev Biochem Mol Biol 45(2):106-124
16. Harten SK, Ashcroft M, Maxwell PH (2010) Prolyl hydroxylase domain inhibitors: A route to HIF activation and neuroprotection. Antioxid Redox Signal 12(4):459-480
17. Chavez A, Miranda LF, Pichiule P, Chavez JC (2008) Mitochondria and hypoxia-induced gene expression mediated by hypoxia-inducible factors. Ann N Y Acad Sci 1147:312-320
18. Avramovich-Tirosh Y, Bar-Am O, Amit T, Youdim MBH Weinreb O (2010). Up-regulation of hypoxia-inducible factor (HIF)-1a and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr Alzheimer Res 7(4): 300-306
19. Kupershmidt L, Weinreb O, Amit T, Mandel S, Bar-Am O, Youdim MB (2011) Novel molecular targets of the neuroprotective/ neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience 189:345-358
20. Kupershmidt L, Amit T, Bar-Am O, Youdim MB, Weinreb O (2012) Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice. Mech Ageing Dev 133(5):267-274
21. Kupershmidt L, Amit T, Bar Am O, Youdim MB, Weinreb O (2012) The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. Antioxid Redox Signal 17 (6):860-877